Dr Agrawal on First-Line Treatment Approaches in HER2+ Breast Cancer
December 5th 2023Laila S. Agrawal, MD, discusses the primary approaches for treating patients with metastatic HER2-positive breast cancer, and highlights the continued exploration of trastuzumab deruxtecan for this patient population.
Read More